Comparison of the effectiveness of alectinib versus crizotinib followed by alectinib in patients with ALK-positive advanced non-small-cell lung cancer in real-world setting and in the ALEX study.

ABSTRACT:

Background

Alectinib has been established as a standard of care for patients with treatment-naive anaplastic lymphoma kinase-rearranged (ALK-positive) advanced non-small-cell lung cancer (NSCLC); however, it has rarely been compared with the sequential approach (crizotinib followed by alectinib) in China. This study aimed to compare real-world alectinib upfront data with either real-world sequential approach data or clinical trial first-line alectinib data.

Methods

The patients who received alectinib in the real-world setting were monitored from August 2016 to November 2020. The patients' characteristics were well balanced using the inverse probability of treatment weighting (IPTW) method. Real-world progression-free survival (rwPFS), real-world overall survival (rwOS), and

SUBMITTER: Yang X 

PROVIDER: S-EPMC12082225 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature